Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α<sub>v</sub>β<sub>3</sub>-Targeted Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) is an emerging approach for patients with unresectable or metastatic tumors. Our previously optimized RGD peptide (3PRGD<sub>2</sub>) has excellent targeting specificity for a variety of integrin α<sub>v</sub>β<sub>3</sub&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/7/1327 |